Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Meningococcal A and C Polysaccharide Conjugate Vaccine
- Development stage
- Unknown
- Lead developer
- Zhifei Biological
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Meningococcal A and C Polysaccharide Conjugate Vaccine, marketed under the brand name **MENINGACON**, is a freeze-dried biologic developed by **Beijing Zhifei Lvzhu Biopharmaceutical**, a subsidiary of Chongqing Zhifei Biological Products. This adjuvant-free vaccine is designed to provide active immunity against *Neisseria meningitidis* serogroups A and C, the primary causative agents of meningococcal meningitis. Each 0.5 mL dose contains 10 μg of group A and 10 μg of group C capsular polysaccharides, each individually conjugated to a tetanus toxoid carrier protein. This conjugation process converts the T-cell independent polysaccharide antigens into T-cell dependent antigens, thereby enhancing immunogenicity and inducing immunological memory, particularly in infants. The vaccine is indicated for individuals aged 3 months and older and is administered via intramuscular injection.
- Brand names
- MENINGACONMening A Con
- Other names
- MenAC conjugate vaccineGroup A and C Meningococcal Polysaccharide Conjugate VaccineMeningococcal A and C Polysaccharide Conjugate Vaccine (Zhifei Lvzhu)
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharide
Beyond the preview
Go deeper on Meningococcal A and C Polysaccharide Conjugate Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Meningococcal A and C Polysaccharide Conjugate Vaccine.